JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.

Slides:

Advertisements

Similar presentations

Tiziano Barbui MD Ospedale Papa Giovanni XXIII Bergamo, Italy

Advertisements

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,

The genetic basis of myelodysplasia and its clinical relevance

THROMBOTIC COMPLICATIONS IN PATIENTS WITH POLYCYTHEMIA VERA Coordinator: Asist. Univ. Dr. Marcela Candea Authors: Ioana-Violeta Oltean Ioana Barsan Madalina.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Good morning… My presentation is about Calreticulin and PMF

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.

Siddharth Sheth, Abuzar Moradi Tuchayi, Roy E Smith

CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening by Maria S. Albano, Patricia Taylor, Robert.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

V617F “JAKs” up myeloproliferative signal

Which mutations matter in myelofibrosis?

European Focus on MPN and MDS 2014

by Mario Cazzola, Marianna Rossi, and Luca Malcovati

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance by Elisabetta Antonioli, Paola Guglielmelli,

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome by Fiorina.

by Adrienne Lee, Steven K. Boyd, Gregory Kline, and Man-Chiu Poon

Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia Fabrice Usseglio, Nathalie Beaufils, Anne Calleja, Sophie.

How we choose factor VIII to treat hemophilia

by Bartlomiej Przychodzen, Andres Jerez, Kathryn Guinta, Mikkael A

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation by Enrico Tiacci, Gianluca Schiavoni, Francesco Forconi,

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Prefibrotisk Myelofibros

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia by Floriana Manodoro, Jacek Marzec, Tracy.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms by Jelena D. Milosevic Feenstra, Harini.

If platelets are not a prognostic factor

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes by Kazuaki Yokoyama, Eigo Shimizu, Nozomi.

by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka

A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies Francesca L. Nice,

Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study by Ada Gillissen, Thomas van den Akker,

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

by Wendy Lim, Sara K. Vesely, and James N. George

Overcoming “aspirin resistance” in MPN

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

by Elisa Rumi, and Mario Cazzola

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.

Rituximab immunotherapy: it’s getting personal

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

How I treat essential thrombocythemia

Balancing bleeding in brain metastases

Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease by Paula Rodriguez-Otero,

Outcomes in patients with PTCL

Presentation transcript:

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela Pietra, Virginia Ferretti, Thorsten Klampfl, Ashot S. Harutyunyan, Jelena D. Milosevic, Nicole C. C. Them, Tiina Berg, Chiara Elena, Ilaria C. Casetti, Chiara Milanesi, Emanuela Sant’Antonio, Marta Bellini, Elena Fugazza, Maria C. Renna, Emanuela Boveri, Cesare Astori, Cristiana Pascutto, Robert Kralovics, and Mario Cazzola Blood Volume 123(10): March 6, 2014 ©2014 by American Society of Hematology

Hematologic parameters in patients with CALR-mutated ET, JAK2 (V617F)-mutated ET, and JAK2 (V617F)-mutated PV. Data are shown in a box plot depicting the upper and lower adjacent values (highest and lowest horizontal line, respectively), upper and lower qua... Elisa Rumi et al. Blood 2014;123: ©2014 by American Society of Hematology

Granulocyte mutant allele burden in JAK2 (V617F)-mutated and in CALR-mutated myeloid neoplasms. Elisa Rumi et al. Blood 2014;123: ©2014 by American Society of Hematology

Relationship between granulocyte JAK2 (V617F)-mutant allele burden and hematologic parameters in patients with ET or PV. The mutant allele burden was directly correlated with Hb level (ρ = 0.53, P <.001) and hematocrit (ρ = 0.61, P <.001), and inversely c... Elisa Rumi et al. Blood 2014;123: ©2014 by American Society of Hematology

Cumulative incidence of polycythemic transformation, thrombotic events, myelofibrotic transformation, and leukemic transformation in patients with CALR- or JAK2-mutated ET and in those with PV. The cumulative incidences were estimated with a competing risk... Elisa Rumi et al. Blood 2014;123: ©2014 by American Society of Hematology